Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) was up 2.2% during mid-day trading on Tuesday . The company traded as high as $19.78 and last traded at $19.60, with a volume of 188,068 shares traded. The stock had previously closed at $19.18.

A number of equities research analysts have weighed in on BLCM shares. SunTrust Banks Inc. started coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price target on the stock. Zacks Investment Research upgraded Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Jefferies Group raised their price target on Bellicum Pharmacueticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Piper Jaffray Cos. restated an “overweight” rating and set a $31.00 price target (up previously from $25.00) on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 9th. Finally, Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $27.00.

The stock’s 50-day moving average price is $15.64 and its 200 day moving average price is $11.75. The company’s market cap is $509.58 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.04. During the same quarter in the previous year, the company earned ($0.40) EPS. Equities analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.32) EPS for the current fiscal year.

In other news, CTO Kevin M. Slawin sold 22,281 shares of the business’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $13.72, for a total transaction of $305,695.32. Following the completion of the sale, the chief technology officer now owns 136,925 shares of the company’s stock, valued at approximately $1,878,611. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CTO Kevin M. Slawin sold 2,719 shares of the business’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $13.99, for a total transaction of $38,038.81. Following the sale, the chief technology officer now directly owns 134,206 shares of the company’s stock, valued at approximately $1,877,541.94. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley raised its position in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent filing with the SEC.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.